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Abstract: Atrial fibrillation (AF) is the most common sustained arrhythmia. Management of 
AF includes rate control, rhythm control if necessary, prevention of thromboembolic events, 
and treatment of the underlying disease. Rate control is usually achieved by pharmacological 
suppression of calcium currents or by applying β-blockers or digitalis compounds. In contrast, 
the number of compounds available for rhythm control is still limited. Class Ic agents increase 
mortality in patients with structural heart disease, and amiodarone harbors an extensive side 
effect profile despite its efficacy in maintaining sinus rhythm.   Furthermore, rhythm control by 
these compounds has not been shown to reduce patient mortality. Dronedarone is a new antiar-
rhythmic drug that has been developed to provide rhythm and rate control in AF patients with 
fewer side effects compared with amiodarone. This review p  rimarily focuses on clinical trials 
evaluating efficacy and safety of the novel drug. Conclusions from these studies are critically 
reviewed, and recommendations for clinical practice are discussed. Dronedarone significantly 
reduced the incidence of hospitalization due to cardiovascular events or death in high-risk 
patients with atrial fibrillation (ATHENA trial). However, dronedarone was less efficient than 
amiodarone in maintaining normal sinus rhythm (DIONYSOS trial) and is contraindicated in 
severe or deteriorating heart failure (ANDROMEDA trial). In summary, dronedarone represents a 
valuable addition to the limited spectrum of antiarrhythmic drugs and is currently recommended 
in patients with paroxysmal and persistent AF to achieve rate and rhythm control, excluding 
cases of severe or unstable congestive heart failure.
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Search strategy
We searched Medline, PubMed, BIOSIS, and Cochrane Library databases for original 
articles, reviews, comments, and meta-analyses. Search terms included: “dronedarone”, 
“atrial fibrillation”, “rhythm control”, “rate control”, “antiarrhythmic therapy”, and 
“ion-channel blocker”. The search focused on publications from the past 5 years but 
did not exclude older publications of general interest. We also searched the reference 
lists of articles identified by this search strategy and selected those we judged relevant. 
Date of last search was 14 November, 2010.
Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia and worsens the 
overall prognosis of patients with cardiovascular diseases by significantly increasing 
the risk of serious cardiovascular complications (eg, heart failure, stroke, cardiovascular 
hospitalization and death).1–6 AF is associated with multiple cardiovascular conditions Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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including arterial hypertension, dyslipidemia, heart failure,   
valvular heart disease, coronary artery disease, and diabetes 
mellitus.7,8 The disease has a current prevalence of 0.95% 
in the United States and is strictly age dependent: 0.1% of 
all individuals under 55 years, but up to 9.0% of those over 
80 years are affected.9 Interestingly, in a p  rojected calcula-
tion AF prevalence was predicted to increase by $2.5-fold 
by the year 2050.10,11
Sustained rapid ectopic activity and reentry represent 
mechanisms that contribute to the development of AF.12–14 
Furthermore, atrial remodeling is an important determinant 
that leads to generation and maintenance of these factors.15 
According to the leading circle theory, reentry circuits are 
favored by short refractoriness and slow conduction.16,17 
The hypothesis of spiral-wave activity proposes a c  irculating 
wave front that rapidly rotates around a central core, 
  depending on tissue excitability and refractoriness as well 
as on central core stability.17–19 Consistent with this theory, 
c  onditions that increase excitability and shorten   refractoriness 
promote AF maintenance by enhancing spiral-wave rotation 
and central core stability. Drugs aiming at suppression of AF 
target these mechanisms. Classic antiarrhythmic Na+-current 
inhibitors (class I drugs) decrease excitability and destabilize 
rotator activity, while K+-channel blocking (or class III) drugs 
suppress reentry mechanisms by extending action potential 
duration and repolarization.20
Traditionally, AF management focuses on stroke preven-
tion and symptom management. Preventing thromboembolic 
complications is a major priority and reduces morbidity 
and mortality, and trials of oral anticoagulant therapy 
demonstrated a substantial risk reduction.21 During AF, 
normal atrioventricular node conduction can lead to rapid 
ventricular rate response, resulting in impairment of left ven-
tricular function and severe limitation of physical activity, 
which is a frequent cause for patient h  ospitalization. Rate 
c  ontrol is usually achieved by pharmacological suppression 
of calcium currents or by applying β-blockers or digitalis 
compounds until heart rate is decreased to a less symptom-
atic state. In contrast, rhythm control aims to convert the 
patient’s heart rhythm to normal sinus rhythm (NSR) and 
to maintain NSR once achieved. Recent studies comparing 
rate and rhythm control strategies (ie, combined results of 
PIAF [Pharmacological Intervention in Atrial Fibrillation], 
STAF [The Strategies of Treatment of Atrial Fibrillation], 
and AFFIRM [Atrial Fibrillation Follow-up Investigation 
of Rhythm Management]) showed that neither achieved 
proven morbidity/mortality benefits, while rhythm control 
using the class III drug amiodarone was associated with 
higher h  ospitalization rates.22–25 On the other hand, class I 
anti  arrhythmic agents have been shown to increase   mortality 
in patients with   struc  tural heart disease.26   Consequently 
American   College of   Cardiology (ACC)/American Heart 
  Association (AHA) 2006, and   European Society of 
C  ardiology (ESC) 2010 guidelines for the   management 
of patients with AF recommended rate control as first-line 
therapy.7,8,22 If the patient remains   symptomatic, therapy 
should be continued or supplemented by an appropriate 
rhythm control drug. Amiodarone is the most frequently 
used antiarrhythmic drug to achieve and maintain NSR.23 
According to the ACC/AHA 2006 and ESC 2010 guidelines, 
amiodarone should be administered at a maintenance dose of 
200 to 400 mg/day.7,8,27 In addition, amiodarone has a heart 
rate lowering effect and can be used simultaneously for rate 
control, particularly if classic rate control agents failed or 
are contraindicated.7,8 However, the use of amiodarone is 
limited by significant adverse effects including decreased 
blood pressure, pulmonary toxicity, skin discoloration, 
thyroid toxicity, corneal deposits, optic neuropathy, and 
sinus bradycardia. As a result, many patients are not eligible 
or refuse to take the drug. Consequently, pharmaceutical 
research has focused on developing more favorable multi-
channel-blocking agents as well as novel ion-channel and 
nonchannel targets.20,28
Dronedarone was approved in July 2009 and is   indicated 
for the treatment of adults with nonpermanent AF to prevent 
recurrence, or to lower ventricular rate. It is a modified deri-
vate of amiodarone and its development   targeted on finding 
a substance combining beneficial antiarrhythmic effects 
without the potential adverse events of amiodarone.
Aims
This review focuses on pharmacological characteristics and 
clinical trial series performed to test efficacy and safety of 
dronedarone in the treatment of atrial fibrillation. Further-
more, morbidity/mortality endpoints evaluated in the largest 
antiarrhythmic drug trial to date, ATHENA (Prevention of 
Cardiovascular Hospitalization or Death from Any Cause in 
Patients with Atrial Fibrillation/Atrial Flutter) are critically 
discussed with respect to current evidence.
Pharmacology
Chemistry29
Dronedarone is a benzofuran molecule, which is chemically 
related to amiodarone. Unlike amiodarone, it does not harbor 
the iodine moieties causing thyroid problems. Moreover the 
addition of a methyl sulfonyl group decreases its l  ipophilicity Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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and shortens its plasma half-life which is thought to reduce 
organ toxicity due to accumulative effects (see Figure 1).
Mechanistic properties
Similar to amiodarone, dronedarone is a multichannel blocker 
that meets criteria of all four Vaughan Williams antiarrhythmic 
drug classes: rate-dependent inhibition of the rapid Na+ current 
(class I), α- and β-adrenergic receptor inhibition (class II), 
blockade of K+ outward currents as the main   mechanism of 
action (class III), and blockade of slow Ca2+ inward currents 
(class IV).30,31 Class I and III effects increase refractory periods 
and decelerate cardiac conduction, p  roviding mechanisms 
that induce rhythm control. Although precise mechanisms of 
dronedarone action are not fully understood, balanced inhibition 
of multiple outward currents may explain the decrease in the 
transmural dispersion of repolarization, which prevents signifi-
cant proarrhythmic effects.32   Furthermore, in contrast to pure 
IK dronedarone increases action potential duration and effective 
refractory period without reverse use-dependency, preventing 
the risk of early afterdepolarization.32,33 In addition, class II and 
IV effects c  ontribute to rate control properties as well as the 
anti-adrenergic (class II) and blood pressure lowering (class IV) 
effects of the drug.34,35 The direct vasodilatatory properties of 
both amiodarone and dronedarone have also been examined.36
Pharmacokinetics/pharmacodynamics29
Absorption
Dronedarone is well absorbed after oral administration 
(.70%). Because of pre-systemic first-pass metabolism, the 
absolute bioavailability is 15% when administered with food, 
as recommended, increasing dronedarone bioavailability by 
2- to 4-fold, due to significant first pass metabolism. After 
oral administration, peak plasma concentrations of drone-
darone and the main circulating active metabolite (N-debutyl 
metabolite) are reached within 3 to 6 hours. Under 400 mg 
twice a day, steady state is reached within 4 to 8 days of 
treatment.
Distribution
The in vitro plasma protein binding of dronedarone and its 
N-debutyl metabolite is 99.7% and 98.5%, respectively, and 
is not capable of saturation. Both compounds bind mainly 
to albumin.
Metabolism
Like amiodarone, dronedarone is metabolized mainly by 
CYP3A4. It forms the predominant circulating metabolite by 
N-debutylation followed by oxidation and oxidative deamina-
tion. The N-debutyl metabolite exhibits pharmacodynamic 
activity, but is 3 to 10 times less potent than dronedarone. 
After oral administration, approximately 6% of the labeled 
dose is excreted in urine and 84% is excreted in feces, both 
mainly as metabolites. The terminal elimination half-life 
of dronedarone is ∼25 to 30 hours and that of its N-debutyl 
metabolite ∼20 to 25 hours. Dronedarone and its metabolite 
applied in a 400 mg twice a day treatment doses are eliminated 
from plasma within 2 weeks after therapy stops. Compared 
with amiodarone, dronedarone has less active metabolites and 
has quicker onset and offset of actions and shorter half-life 
as well as a smaller volume of distribution.
Pharmacodynamics
Electrocardiographic changes include a dose-related decrease 
of heart rate at rest and under exercise, and moderate increase 
of PR- and QTc-intervals. In addition moderate lowering of 
blood pressure was observed.37 Furthermore an increase of 
serum creatinine levels by about 0.1 mg/dL was detected, 
reaching plateau after 7 days of treatment and being revers-
ible after discontinuation of the drug. A similar effect has 
been demonstrated with amiodarone.38 These effects have 
been shown to result from an inhibition of tubular creati-
nine secretion without affecting glomerular filtration rate.39 
However, serum creatinine levels should be checked 1 week 
after onset of drug administration.
Pharmacokinetic variability and pharmacodynamic 
interactions
The main sources of pharmacokinetic variability identified 
are age, gender, and weight, but they all have only modest 
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Figure 1 Chemical structure of dronedarone A). The substance is based on a 
benzofuran molecule and does not possess the iodine moieties (red frame) causing 
thyroid problems associated with amiodarone B). The addition of a methyl sulfonyl 
group (green frame) decreases its lipophilicity and shortens its plasma half-life to 
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effects. Furthermore congestive heart failure, renal   function, 
and even severe renal impairment do not significantly 
i  nfluence pharmacokinetics of dronedarone, and thus no 
dose adjustment is required. Moderate hepatic impairment 
alters pharmacokinetics by a 1.3-fold increase of steady-state 
dronedarone exposure, while active metabolite exposure 
decreased by 1.6- to 1.9-fold. Concomitant pharmacody-
namic changes in ECG parameters were not detected. No 
dosage adjustment is recommended for moderate hepatic 
impairment, but dronedarone is contraindicated in severe 
hepatic failure.29
The primary extrinsic factors that influence pharmacoki-
netics of dronedarone are modulators of CYP3A4. The use 
of strong CYP3A inhibitors (eg, ketoconazole) together with 
dronedarone is contraindicated, and grapefruit juice should 
also be avoided.
Dronedarone can significantly increase statin levels by 
2- to 4-fold and clinical signs of muscular toxicity should 
be monitored. Notably, pharmacodynamic interactions can 
be expected with β-blockers, calcium channel blockers and 
digoxin. Drugs that prolong the QT interval, potentially 
inducing torsade de pointes (TdP) tachykardia, such as 
phenothiazines, cisapride, bepridil, tricyclic antidepressants, 
oral macrolides and class I and III antiarrhythmic drugs are 
contraindicated. Only mild interaction was observed between 
dronedarone and warfarin with no clinically significant 
increase in international normalized ratio (INR). Pregnancy 
and nursing are both considered contraindications to drone-
darone. It may cause fetal harm and thus should be avoided 
during pregnancy or in those who may become pregnant. 
Furthermore dronedarone may pose potential harm in nurs-
ing infants. The safety and efficacy of dronedarone have not 
been proven in children below the age of 18 years.
Clinical trials
DAFNe37
The DAFNE (Dronedarone Atrial Fibrillation study after 
Electrical Cardioversion) trial was designed as a phase II 
trial to establish the appropriate dose of dronedarone for 
preventing recurrence of AF after cardioversion in patients 
with persistent AF. DAFNE was a multinational, multi-
center, prospective double-blind, placebo-controlled trial. 
Eligible patients showing persistent AF for $72 hours 
and ,12 months duration were randomized to receive either 
placebo or dronedarone tablets 400 mg twice a day, 600 mg 
twice a day or 800 mg twice a day for a planned duration 
of 6 months. Patients who did not convert to NSR within 
5 days after onset of medication were treated by electrical 
cardioversion. The primary endpoint included the time to 
first AF recurrence. Secondary endpoints were defined as 
spontaneous conversion of AF following randomization, 
heart rate in case of AF recurrence, and incidence of side 
effects. Patients included totaled 270, and 50 active centers 
in 11 countries contributed to the study.
Dronedarone 400 mg twice a day significantly increased 
the time to first recurrence of AF compared with placebo. 
The 400 mg twice a day dose showed best results in terms 
of efficacy and safety. Gastrointestinal (GI) side effects were 
the most frequent adverse event in the dronedarone groups. 
Although rare in the 400 mg twice a day group (1.3% of 
patients discontinued because of GI problems), patients in 
the 800 mg twice a day group frequently reported GI prob-
lems and showed significant QT prolongation. Furthermore 
DAFNE demonstrated a significant lowering of ventricular 
rate of patients who relapsed into AF. In conclusion DAFNE 
identified 400 mg twice a day as the best dosage of drone-
darone for further testing in phase III trials.
eURiDiS/ADONiS40
EURIDIS (European Trial in Atrial Fibrillation or Flutter 
Patients Receiving Dronedarone for the Maintenance of Sinus 
Rhythm) and ADONIS (American-Australian Trial with 
Dronedarone in Atrial Fibrillation of Flutter Patients for the 
Maintenance of Sinus Rhythm) were initiated to assess the 
efficacy of dronedarone for maintaining NSR after electrical, 
pharmacological or spontaneous conversion from paroxysmal 
or persistent AF or atrial flutter (AFL). The studies were 
designed as double-blind, parallel-arm, placebo-controlled 
phase III trials and randomized 612 and 625 patients, 
r  espectively. Inclusion criteria included more than one AF 
episode within the previous 3 months. Patients with NYHA 
(New York Heart Association) class III or IV were excluded. 
The primary endpoint was the time to first r  ecurrence of AF/
AFL. Secondary endpoints included symptomatic AF/AFL 
among   adjudicated first AF/AFL recurrence, time between 
steady state and adjudicated first AF/AFL recurrence, mean 
ventricular rate during first AF recurrence, and cardiovas-
cular hospitalization. Some patients in both arms received 
basal therapy for rate-control (β-blocker, calcium-channel 
blocker, digoxin) and additional cardiovascular medica-
tion. In conclusion, dronedarone was superior to placebo in 
preventing recurrence of AF with 64.1% of patients having 
AF recurrence at 12 months compared with 75.2% in the 
placebo group (P , 0.001). Moreover dronedarone was also 
effective in controlling ventricular rates after AF relapse, as 
ventricular rates were 14 bpm slower than in the placebo Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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group (P , 0.001). Adverse event rate was similar between 
the drug and placebo. No TdP tachycardia occurred and there 
was no evidence of organ toxicity.   However a slight increase 
in serum creatinine levels was observed in the dronedarone 
group, which returned to baseline when the drug was dis-
continued. Pooled post-hoc analysis of EURIDIS/ADONIS 
showed that dronedarone significantly reduced the relative 
risk of all-cause hospitalization or death by 27% compared 
with placebo (P = 0.01), which was further investigated in 
the ATHENA trial.
eRATO41
The objective of ERATO (European Study of Dronedarone 
in Atrial Fibrillation) was to evaluate the efficacy of drone-
darone for the control of mean 24-hour ventricular rate in 
patients with symptomatic, permanent AF, when added to 
concomitant therapy (ie, β-blockers [excluding sotalol], 
calcium-channel blockers, digoxin). The multicenter, 
double-blind, parallel-arm trial randomized 174 patients 
to receive either placebo or dronedarone 400 mg twice 
a day for 6 months. The primary endpoint was the mean 
24-hour ventricular rate after 2 weeks. Secondary endpoints 
included ventricular rate during submaximal and maximal 
exercise after 2 weeks, change in maximal exercise dura-
tion after 2 weeks, and mean 24-hour ventricular rate after 
4 months.
Dronedarone decreased the 24-hour ventricular rate by 
11.7 bpm (P , 0.0001) and the maximum exercise ventricular 
rate by 24.5 bpm (P , 0.0001), which was achieved on top 
of baseline medication including classic rate control drugs. 
There was no significant difference in exercise duration from 
baseline in either group, indicating that dronedarone benefits 
were achieved without impairing exercise capacity. This effect 
was sustained during long-term treatment (6 months). Serious 
adverse events were experienced by 17% of patients in the 
dronedarone group vs 14% in the placebo group, and the dis-
continuation rate was 15% in the dronedarone group vs 10% 
in the placebo group. These differences were nonsignificant. 
No evidence of organ toxicity or proarrhythmia was apparent 
in the dronedarone group. Frequent adverse events included 
infections (31% in the dronedarone group vs 25% in the 
placebo group) and gastrointestinal side effects (20% in the 
dronedarone group vs 14% in the placebo group) and were 
not significantly different between the groups.
ANDROMeDA42
ANDROMEDA (Antiarrhythmic Trial with Dronedarone in 
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aimed at assessing potential benefit of dronedarone on 
all-cause mortality and hospitalization for worsening heart 
failure in high risk patients with congestive heart failure 
(NYHA III-IV or recent decompensation). Among study 
patients, 25% showed AF at randomization. The phase III 
trial design was multi-center, double-blind, parallel-arm and 
placebo-controlled. Patients were randomized into the drone-
darone 400 mg twice a day or placebo groups. These totaled 
627 patients who were hospitalized with new or worsening 
heart failure, and who had experienced at least one episode of 
shortness of breath on minimal exertion or at rest, or who had 
paroxysmal nocturnal shortness of breath within the month 
before admission (NYHA III-IV), and who showed a wall-
motion index at screening not exceeding 1.2 (left ventricular 
ejection fraction [LVEF] 35% or less).   Primary endpoint 
was defined as death from any cause or hospitalization for 
worsening heart failure. Secondary endpoints included death 
from all causes, hospitalization for worsening heart failure, 
occurrence of AF/AFL, death from arrhythmia, or sudden 
death. The trial was prematurely stopped by the independent 
safety monitoring board after 7 months of first randomiza-
tion because of an excess of deaths in the dronedarone arm. 
A total of 627 patients (310 in the dronedarone and 317 in 
the placebo group) had been enrolled up to the termination 
of the study. During a median follow-up of 2 months, 25 
patients in the dronedarone group (8.1%) and 12 patients 
in the placebo group (3.8%) died (hazard ratio [HR] of 
dronedarone, 2.13; 95% confidence interval [CI], 1.07–4.25; 
P = 0.03). The excess mortality was predominantly related to 
worsening heart failure, which accounted for 10 deaths in the 
dronedarone group compared with 2 in the placebo group. 
No case of death due to TdP tachycardia was reported. Sub-
group analysis indicated that risk was increased in patients 
with a low wall-motion index. However, the most powerful 
predictor of death was treatment with dronedarone (HR, 
2.19; 95% CI, 1.06–4.52; P = 0.03). No statistical differ-
ence in the primary endpoint was detected between the two 
groups (HR, 1.38; 95% CI, 0.92–2.09; P = 0.12). Serious 
adverse events included more cases of increased creatinine 
concentration in the dronedarone group than in the placebo 
group. As a consequence of ANDROMEDA, patients with 
an unstable hemodynamic situation were excluded from the 
ATHENA trial.
ATHeNA43
The study was designed to evaluate the efficacy and safety 
of dronedarone 400 mg twice a day vs placebo for the pre-
vention of cardiovascular hospitalization or death from any 
cause over a minimum treatment and follow-up duration 
of 12 months. Patients at risk with ECG-documentation 
of both AF/AFL and NSR within the last 6 months were 
included. The rationale was that AF is associated with 
several cardiovascular diseases that influence outcome. 
Therefore a combined primary endpoint of cardiovascular 
hospitalization or death was chosen to assess benefits of 
the drug. Secondary endpoints included death from any 
cause, cardiovascular death, and first hospitalization for 
cardiovascular reasons.
ATHENA is the largest single antiarrhythmic drug trial 
ever conducted. This multinational, multicenter, placebo-
controlled, double-blind, parallel-arm randomized trial 
enrolled a total of 4628 patients; 2301 patients were ran-
domly assigned to receive dronedarone and 2327 to receive 
placebo. Patients aged 75 years or older with or without 
additional risk factors were eligible. In addition, patients at 
least 70 years of age were enrolled when exhibiting one or 
more of the f  ollowing risk factors: hypertension, diabetes, 
prior stroke/transient ischemic attack or systemic embolism, 
left atrial diameter $50 mm, and LVEF ,40%. Initially, the 
protocol had also allowed the inclusion of younger patients 
with a  dditional risk factors. During the trial, overall mortality 
  figures were lower than expected. Thus the steering com-
mittee had recommended changing the inclusion criteria to 
enrich the risk profile of the overall study population and 
patients younger than 70 years of age were no longer eligible. 
Patients included were of higher risk than the EURIDIS/
ADONIS study population.40,43 Exclusion criteria included 
permanent AF, congestive heart failure, NYHA class 4 within 
the last 4 weeks, and concomitant use of antiarrhythmic 
drugs or potent CYP3A4 inhibitors. Patients with NSR were 
directly randomized; AF/AFL was treated by cardioversion 
to achieve NSR before randomization.43 The mean follow-up 
period was 21 ± 5 months.
A primary outcome event occurred in 734 patients 
(31.9%) in the dronedarone group and in 917 patients 
(39.4%) in the placebo group (HR for dronedarone, 0.76; 
95% CI, 0.69–0.84; P , 0.001). Overall deaths from any 
cause occurred in 116 patients (5.0%) in the dronedarone 
group and 139 patients (6.0%) in the placebo group (HR for 
dr  onedarone, 0.84; 95% CI, 0.66–1.08; P = 0.18). Deaths from 
cardiovascular causes were lower in the dronedarone group 
(63 patients, 2.7%) than in the placebo group (90 patients, 
3.9%; HR 0.71; 95% CI, 0.519–0.98; P = 0.03).
Adverse events occurred more often in the dronedarone 
group (12.7%) than in the placebo group (8.1%) and most 
frequently were of GI cause (26% vs 22%). Bradycardia, Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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QT- prolongation, diarrhea, nausea, rash, and increase in the 
serum creatinine level were significantly more common in 
the dronedarone group than in the placebo group. One single 
case of TdP tachycardia occurred in the dronedarone group. 
There were no significant differences in terms of organ toxic-
ity, namely pulmonary symptoms, interstitial lung disease, 
and thyroid dysfunction.
Post hoc analysis of ATHENA data indicated that drone-
darone decreases the risk of stroke in AF.43   Dronedarone 
reduced the stroke rate from 1.8% per year to 1.2% per 
year (HR, 0.66; 95% CI, 0.46–0.96, P = 0.027). The effect 
of dronedarone was similar whether or not patients were 
receiving oral anticoagulant therapy, and there was a sig-
nificantly greater effect of dronedarone in patients with 
higher CHADS2 scores (mean CHADS2 score was 2 in the 
ATHENA population). In addition dronedarone on top of 
standard therapy significantly reduced the relative risk of 
first cardiovascular hospitalization (HR, 0.74; P , 0.001).44,45 
Furthermore, rhythm and rate control properties in ATHENA 
were objective of secondary analyses: the median time to first 
AF recurrence of patients in NSR at baseline was prolonged 
from 498 days in placebo patients to 737 days with drone-
darone (HR, 0.75; P , 0.001) and dronedarone reduced the 
median heart rate in AF by 9 bpm compared with placebo 
(75 vs 84 bpm; P , 0.001).46
DiONYSOS47
The DIONYSOS (Efficacy and Safety of Dronedarone 
Versus Amiodarone for the Maintenance of Sinus Rhythm 
in Patients With Atrial Fibrillation) trial investigated safety 
and efficacy of dronedarone compared with amiodarone 
for the maintenance of NSR in patients with persistent AF 
in a short-term study with a median treatment duration of 
7 months. Inclusion criteria comprised patients with ECG-
documented AF for more than 72 hours for whom cardiover-
sion and antiarrhythmic treatment was indicated. Exclusion 
criteria were AFL, contraindication to oral anticoagulation or 
to amiodarone, and paroxysmal AF. The trial was conducted 
in a multinational, multicenter, double-blind, parallel-arm, 
placebo-controlled fashion. Patients (504) were random-
ized either to a dronedarone 400 mg twice a day group 
(249 patients) or to an amiodarone group (255 patients), 
receiving 600 mg loading dose daily for 28 days, and a 
maintenance dose of 200 mg daily thereafter. Electrical 
cardioversion was performed between days 10 and 28 if the 
patient had not converted to NSR spontaneously.
The composite primary endpoint was AF recurrence 
or premature study discontinuation for intolerance or 
lack of efficacy. The study also defined a main safety 
e  ndpoint (MSE) of predefined thyroid, hepatic, pulmonary, 
n  eurological, skin, ocular and GI adverse events, as well as 
premature drug d  iscontinuation due to any adverse event. 
Furthermore analysis of individual components of the 
MSE, and the MSE excluding GI adverse events, served as 
s  econdary endpoints.
The primary composite endpoint was in favor of amio-
darone (HR, 1.59; 95% CI, 1.28–1.98; P , 0.0001) and was 
driven mainly by the AF recurrence component, demonstrat-
ing that dronedarone was less effective than amiodarone in 
terms of prevention of AF recurrence (36.5% vs 58.0%), 
while on the other hand, the premature drug discontinua-
tion component was less frequent in the dronedarone group 
(10.4% vs 13.3%, respectively).
Analysis of the MSE suggested that dronedarone may 
have a more favorable safety profile. Incidence of MSE 
was 39.3% and 44.5% in the dronedarone and amiodarone 
groups, respectively at 12 months treatment (HR, 0.8; 95% 
CI, 0.6–1.07; P = 0.13). The reduced MSE in the dronedarone 
group was mainly due to fewer thyroid, neurological, skin and 
ophthalmologic events. However, more GI events (mainly 
diarrhea) were documented in the dronedarone group than in 
the amiodarone group (9.2 vs 3.1% respectively of patients 
who had had least one episode of diarrhea). A prespecified 
endpoint focusing only on more clinically severe adverse 
events, excluding GI events, showed a statistically significant 
relative risk reduction in favor of dronedarone (HR, 0.61; 
95% CI, 0.44–0.84; P = 0.002). Moreover, fewer patients 
receiving dronedarone developed bradycardia (defined as 
heart rate ,50 bpm and decrease from baseline .20 bpm) 
compared with amiodarone (19.0% vs 29.5%; P = 0.0067) 
and QTc-interval (Bazett) prolongations .500 ms were 
reported in 10.9% vs 20.5% of patients, respectively 
(P = 0.0033). The overall incidence of adverse events lead-
ing to permanent drug discontinuation was 12.9% in the 
dronedarone group compared with 17.6% in the amiodarone 
group and was mainly driven by QT-prolongation and hypo- 
or hyperthyroidism.
Importantly there was an interaction between amio-
darone and oral anticoagulants leading to supratherapeutic 
INR (.4.5) levels associated with increased incidence of 
hemorrhagic events (number of bleeding events: 5.6% in 
dronedarone and 11.4% in amiodarone groups; P = 0.03). 
Moreover, dronedarone had an antihypertensive effect 
compared with amiodarone, which may contribute to ben-
eficial effects on cardiovascular outcome observed in the 
ATHENA trial. There were no outcome data evaluated in Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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the   DIONYSOS trial. As a limitation of the study, authors 
stressed that short study-duration might have led to an 
underestimation of the adverse events in patients treated 
with amiodarone, since pulmonary events usually occur up 
to 2 years after initiation of amiodarone therapy.48
Ongoing trials
The PALLAS (Permanent Atrial fibrillation outcome Study 
using Dronedarone on top of standard therapy) trial started 
randomization in summer 2010, and is focused on patients 
with permanent AF and additional risk factors. It aims at 
prevention and reduction of cardiovascular outcome in 
these patients. The primary endpoint is defined as major 
cardiovascular events (stroke, systemic arterial embolism, 
myocardial infarction, or cardiovascular death) and first 
unplanned cardiovascular hospitalization or death from 
any cause.
The ARTEMIS AF (A Randomized, international, 
multicenter, open-label study to document optimal timing 
of initiation of dronedarone Treatment after conversion with 
loading dose of amiodarone in patients with persistent atrial 
fibrillation requiring conversion of Atrial Fibrillation) trial 
started randomization in summer 2010, and addresses the 
optimal regimen for dronedarone initiation following amio-
darone discontinuation. It is divided into two sub-studies: 
the ARTEMIS AF loading trial starts at conversion with 
loading dose of amiodarone in patients with persistent AF 
requiring conversion of AF. The ARTEMIS AF long-term 
trial examines the initiation of dronedarone after long-term 
amiodarone in patients with paroxysmal or persistent AF, 
whatever the reason for change of treatment was.
Concluding remarks
The results of the ATHENA trial provided reassurance about 
the use of dronedarone. In particular, safety concerns raised 
by the results of the ANDROMEDA trial were addressed. 
In both trials patients with low LVEF and NYHA class II or III 
were included, but the ANDROMEDA population had been 
hospitalized for deterioration of heart failure, while stable out-
patients were enrolled in the ATHENA trial. Further analysis 
performed by the manufacturer indicated why patients with 
LVEF ,35% and NYHA class III heart failure responded 
differently in the two trials. They concluded that clinical 
instability rather than LVEF or NYHA classification may be 
an important determinant of the treatment response to drone-
darone. Because of lessons learned from A  NDROMEDA, 
the FDA Cardiovascular and Renal Drugs Advisory 
C  ommittee prompted the drug to be contraindicated in heart 
failure NYHA classes III-IV or unstable NYHA class II.29 
Owing to partially overlapping populations of ATHENA and 
ANDROMEDA, it appears premature to assume safety for 
the use in patients with advanced heart f  ailure. Even if heart 
failure is in a stable chronic state, patients should be monitored 
for worsening of symptoms to discontinue dronedarone in 
case of deterioration. Further investigations need to identify 
more clearly populations taking advantage of, or being at risk 
during dronedarone therapy.
On the other hand, the DIONYSIS trial showed that 
dronedarone is less efficient than amiodarone in decreasing 
AF recurrence. At the same time, the trial indicated a more 
favorable side effect profile. In particular,   dronedarone 
showed fewer thyroid, neurological, skin and ocular events, 
despite the fact that GI events were more frequent. For   clinical 
practice the critical question is whether these potential ben-
efits justify a retreat from the more efficient amiodarone. 
It is estimated that for every 1000 patients treated with 
dronedarone instead of amiodarone, there will be 228 more 
recurrences of AF per year in exchange for 9.6 fewer deaths 
and 62 fewer adverse events requiring drug discontinuation. 
This estimation is based on the assumption that indirect 
meta-analysis results are given the same approximate weight 
as the DIONYSOS direct comparison.49
There was no interaction between dronedarone and oral 
anticoagulants leading to a significantly reduced incidence 
of hemorrhagic events compared with amiodarone, an 
important issue for therapy of a disease that often requires 
oral anticoagulation. The transition from other antiarrhyth-
mic drugs (  including amiodarone to dronedarone and vice 
versa) requires special attention. In the ANDROMEDA 
and ATHENA   trials, amiodarone was discontinued at least 
4 weeks before   randomization. Other class I or III drugs 
were stopped for at least 5 plasma half-lives before the first 
dose of dronedarone. Pending r  eliable data (ARTEMIS AF), 
one should adopt these r  ecommendations for daily practice. 
Furthermore, transition from dronedarone to a different 
antiarrhythmic agent requires a drug-free interval of at least 
5 plasma half-lives (∼1 week) after cessation of treatment 
with dronedarone.
Generally, one might ask what kind of benefit could 
be expected from another drug with less antiarrhythmic 
efficacy, but better tolerance than generically available 
amiodarone.50,51 In this context, the ATHENA trial eluci-
dated mortality/  morbidity criteria beyond AF recurrence 
to address   implications of dronedarone in cardiovascular Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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disease   associated with AF. Indeed, in addition to rhythm 
and rate control, ATHENA indicated outcome benefits of 
dronedarone in patients with AF and concomitant risk factors. 
Primary endpoint of the study was a combined endpoint of 
cardiovascular hospitalization or death, but the results were 
mainly driven by a lower hospitalization rate in the drone-
darone (29.3%) than in the placebo group (36.9%), whereas 
deaths from any cause showed no significant difference. 
Further analysis indicated that death from cardiovascular 
cause was significantly lower in the dronedarone group 
than in placebo, but results have to be judged with caution. 
According to the FDA because of a pre-specified hierarchical 
procedure to control global type I error at the 5% level, car-
diovascular death can only be tested if death from any cause 
is significant.29 Thus,   further evidence with respect to total 
mortality will be needed in order to demonstrate clearly, hard 
endpoint benefits. In contrast, amiodarone did not improve 
cardiovascular morbidity or mortality. A recent meta-analysis 
in a large cohort of 12 studies revealed that while amiodarone 
was a potent antiarrhythmic drug, e  ffective in achieving and 
maintaining NSR in persistent AF (P , 0.00001 vs placebo), 
effects on mortality or hospitalization could not be shown.52
Moreover, dronedarone was effective in controlling 
ventricular rate after AF relapse as observed in EURIDIS/
ADONIS and achieved significant rate control in   permanent 
AF as demonstrated by ERATO. Thus, dronedarone 
offers adequate treatment for rate control, and other than 
  amiodarone, provides these effects without the price of 
intolerance and organ toxicity.
Based on the results of previous clinical trials, we con-
clude that dronedarone moderately reduces the incidence 
of AF relapses and offers an additional treatment option 
for rate control. Compared with amiodarone, dronedarone 
exhibits less efficacy but suggests better tolerance, pend-
ing long-term safety data. Furthermore, given that amio-
darone is ineffective on cardiovascular hospitalization or 
death,52 dronedarone, beyond decreasing AF episodes, 
reduces cardiovascular hospitalizations and may reduce 
cardiovascular mortality.43 Notably, dronedarone is con-
traindicated in decompensating heart failure and NYHA 
classes III–IV. Considerations prior to initiating treatment 
with dronedarone in an individual patient should include 
the underlying disease (ie, heart failure), concomitant 
drugs (ie, oral anticoagulation, CYP3A4 inhibitors), basal 
heart rate, length of the QT interval, priority of maintain-
ing NSR, and contraindications against amiodarone or 
class Ic agents.
In future studies, the antiarrhythmic potency of 
  dronedarone should be directly compared with other anti-
arrhythmic drugs (eg, sotalol, class Ic agents) to evaluate 
efficacy and safety. Furthermore, questions remain regarding 
long-term safety benefits (organ toxicity) compared with 
amiodarone, as DIONYSOS was conducted as a short-term 
trial only. Future studies will have to clarify the drug’s impact 
on overall mortality, particularly in patients with heart failure. 
ATHENA and ANDROMEDA raised questions concerning 
the outcome in patients with moderate to severe conges-
tive heart failure at risk of further deterioration. Moreover, 
potential benefits for the reduction of stroke risk have to be 
studied using prespecified endpoints, as current data from 
ATHENA subanalysis43 indicating reduction of stroke risk by 
dronedarone were obtained only by post-hoc analysis.
In addition, the benefit of dronedarone in patients after AF 
recurrence compared with classic rate control agents would 
be of interest. In particular, data on rate control properties of 
dronedarone independent from underlying baseline m  edication 
are lacking, preventing comparison with standard rate control 
approaches.29 Finally, the application of dronedarone in the 
management of additional arrhythmias (ie,   ventricular tachy-
cardia) may be evaluated in the near future.
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